about
Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or BA generalised model for individualising a treatment recommendation based on group-level evidence from randomised clinical trialsGender-differences in disease distribution and outcome in hospitalized elderly: data from the REPOSI study.Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data.Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study.Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor. Patient Data Meta-analysis of rAFH-PFM Post-Authorization Safety Studies.Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol.Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review.Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey.Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysisInhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression.A tutorial on sensitivity analyses in clinical trials: the what, why, when and how.Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM.Predictors of clinical events occurring during hospital stay among elderly patients admitted to medical wards in Italy.Management of patients with unprovoked venous thromboembolism: an evidence-based and practical approachEfficacy of ultra-micronized palmitoylethanolamide (um-PEA) in geriatric patients with chronic pain: study protocol for a series of N-of-1 randomized trials.Bayesian approach to the assessment of the population-specific risk of inhibitors in hemophilia A patients: a case study.Clinical trials and haemophilia: does the Bayesian approach make the ideal and desirable good friends?Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.Perioperative management of antiplatelet therapy in patients with a coronary stent who need noncardiac surgery: a systematic review of clinical practice guidelines.Influenza vaccination and vitamin K antagonist treatment: a placebo-controlled, randomized, double-blind crossover study.Mild cognitive decline. A position statement of the Cognitive Decline Group of the European Innovation Partnership for Active and Healthy Ageing (EIPAHA).Building Bridges for Innovation in Ageing: Synergies between Action Groups of the EIP on AHA.Emergency physician accuracy in interpreting electrocardiograms with potential ST-segment elevation myocardial infarction: Is it enough?Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People.Changes in clinical outcomes for community-dwelling older people exposed to incident chronic polypharmacy: a comparison between 2001 and 2009.A decisional model to individualize warfarin recommendations: Expected impact on treatment and outcome rates in a real-world population with atrial fibrillation.Gender difference in drug use in hospitalized elderly patients.Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia.Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards.Prophylaxis of venous thromboembolism in elderly patients with multimorbidity.Patient-level compared with study-level meta-analyses demonstrate consistency of D-dimer as predictor of venous thromboembolic recurrences.The stigma of low opioid prescription in the hospitalized multimorbid elderly in Italy.Prognostic value of estimated glomerular filtration rate in hospitalized elderly patients.Comparison of disease clusters in two elderly populations hospitalized in 2008 and 2010.Drug-drug interactions in a cohort of hospitalized elderly patients.Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study.Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly.Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study.Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF.
P50
Q24195006-F5001E12-9314-4B16-8F69-541AB19C0AABQ30543580-2101F86F-81A9-4394-A02A-D34459685067Q30837974-B9D81275-CB23-4B63-9172-47F09D1F73F6Q30889099-BA5D1778-141C-43A6-93F4-51788965FB89Q30906342-3B4F53FD-6564-4344-AC4D-A4154D209EC1Q30959893-1BB4B717-B141-4CB7-9BAB-50F7248D9B30Q31088061-FFF003AC-118D-481E-9EE5-C0A43418E183Q34145656-7FB4F987-9263-4AAF-9276-C7EB7ABAB1EAQ34420450-D2918F88-3415-4280-9FE0-896B9E300662Q34603112-868118E8-4A40-48F5-BDBE-D6BA5FEFA480Q34784564-A6A138B0-05F1-415F-BADD-9E54A32E184EQ34819923-51CD617B-A684-4FAF-B603-521276426D4DQ35209354-5BB9ADBC-53AB-47CB-9D5D-00C490D32B44Q36011737-F355E073-52C2-44D8-8B28-A794903B19D1Q36718482-831C6462-A16B-4780-97FF-7DF41F8B327EQ37138714-7227B56F-ABA3-40BC-83EA-12C8354C42A3Q37381565-3D1AAFEF-8AA7-4948-AC75-CD32E30A0DDEQ37497562-873A0433-572D-4422-B39C-47571B0F0F5FQ37719683-884C384B-0136-444B-97F3-B85BDD46C8AEQ38127571-598F663D-14A4-45BB-95DF-5265F88675D2Q38374411-424F3D86-0F13-45CE-A09F-B8D708C12013Q38621153-DFEFB9E8-D9F9-4E7E-A880-6603FCA56F68Q38779963-FDA0C72C-4687-458C-8422-1A5660FB445CQ39271833-7A3145F2-4556-4E42-AE7F-0079C15723C2Q40181568-47992C9F-8AA8-4FE5-8B8B-7483FEDC3DFEQ40188560-563DBBFD-C4FA-4EC3-BDAB-2D2CF3FE6AE0Q40287579-C34D098C-C57D-4545-8322-AB7A6B3A29E4Q40697364-52B4D32C-3C17-4DC1-9E54-41D842020807Q41033872-32BC19E0-5524-4D4D-A6DB-D0339BE40EE1Q42791455-8D6F8D5D-DFB7-4A53-8EB5-895474732171Q43513337-3A996873-828C-4E02-8A29-E0FBBAC6440EQ43691261-C53C2D88-32E0-471D-876C-AF44AC673783Q44347241-DC3DC20E-D798-4B92-BD4C-4C7CB8ACD395Q44452297-9DAD66E8-59A9-4695-8209-91F1082EF2C9Q44500986-6C21E460-1124-4505-A7AA-C33C7A7044A7Q44670806-2B0B6B2B-D3C5-42B4-AEC0-78D4C06B3885Q44881260-919606C4-EEFB-4718-98DB-DC092CF63A6DQ45739067-6157CBD0-B447-4AF5-BCF9-A7FB0452C33AQ45764426-2E558A44-A3B8-42DD-B06D-F838298DA828Q45863853-7ACC7740-5D16-4ECE-94C7-341F74817A29
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Maura Marcucci
@ast
Maura Marcucci
@en
Maura Marcucci
@es
Maura Marcucci
@nl
Maura Marcucci
@sl
type
label
Maura Marcucci
@ast
Maura Marcucci
@en
Maura Marcucci
@es
Maura Marcucci
@nl
Maura Marcucci
@sl
prefLabel
Maura Marcucci
@ast
Maura Marcucci
@en
Maura Marcucci
@es
Maura Marcucci
@nl
Maura Marcucci
@sl
P106
P1153
56750461100
P21
P214
1839148753682841320005
P31
P496
0000-0002-8468-7991
P734
P7859
viaf-1839148753682841320005